MB310

MB310 is a live biotherapeutic product being developed by Microbiotica for ulcerative colitis. It contains a defined combination of eight live bacterial strains normally associated with the gut. Microbiotica formulated MB310 as an oral capsule for daily administration. Its design focuses on the intestinal epithelial barrier and the immune processes involved in the disease. [Developer description](https://Microbiotica.com/Microbiotica-raises-36-million-48-million-in-series-c-financing-to-advance-pipeline-into-phase-2-clinical-development/)

The strains were selected through analysis of clinical and microbiome data from a faecal microbiota transplant study. Microbiotica identified bacteria associated with clinical response and used them to develop a defined product. Laboratory studies have examined several ways its strains may support barrier Integrity. Those proposed mechanisms explain the treatment approach; they do not establish how well the investigational medicine will work in patients. [Research background](https://Microbiotica.com/Microbiotica-unveils-multiple-mechanisms-by-which-MB310-in-clinical-development-for-the-treatment-of-ulcerative-colitis-protects-the-intestinal-barrier/)